A modeling analysis of monoclonal antibody percolation through tumors: a binding-site barrier
- PMID: 2362198
A modeling analysis of monoclonal antibody percolation through tumors: a binding-site barrier
Abstract
For successful use of radiolabeled monoclonal antibodies (MAbs) for diagnosis and therapy, it is helpful to understand both global and microscopic aspects of antibody biodistribution. In this study, antibody distribution in a tumor is simulated by splicing together information on global pharmacokinetics: transport across the capillary wall, diffusive penetration through the tumor interstitial space, and antigen-antibody interaction. The geometry simulated corresponds to spherical nodules of densely packed tumor cells. This modeling analysis demonstrates that: 1) antigen-antibody binding in tumors can retard antibody percolation; 2) high antibody affinity at a given dose tends to decrease antibody percolation because there are fewer free antibody molecules. The result is a more heterogeneous distribution; 3) the average antibody concentration in the tumor does not increase linearly with affinity; and 4) increasing antibody dose leads to better percolation and more uniform distribution. This mathematical model and the general principles developed here can be applied as well to other biologic ligands.
Similar articles
-
Heterogeneity of monoclonal antibody distribution and radiation dose in tumors: a modeling analysis.Hokkaido Igaku Zasshi. 1991 May;66(3):369-84. Hokkaido Igaku Zasshi. 1991. PMID: 1885162
-
Integrated microscopic-macroscopic pharmacology of monoclonal antibody radioconjugates: the radiation dose distribution.Cancer Res. 1991 Sep 15;51(18):4821-7. Cancer Res. 1991. PMID: 1893374
-
Modeling analysis of the global and microscopic distribution of immunoglobulin G, F(ab')2, and Fab in tumors.Cancer Res. 1989 Oct 15;49(20):5656-63. Cancer Res. 1989. PMID: 2790783
-
Early intervention in cancer using monoclonal antibodies and other biological ligands: micropharmacology and the "binding site barrier".Cancer Res. 1992 May 1;52(9 Suppl):2747s-2751s. Cancer Res. 1992. PMID: 1563006 Review.
-
The macroscopic and microscopic pharmacology of monoclonal antibodies.Int J Immunopharmacol. 1992 Apr;14(3):457-63. doi: 10.1016/0192-0561(92)90176-l. Int J Immunopharmacol. 1992. PMID: 1618598 Review.
Cited by
-
Application of PBPK modeling to predict monoclonal antibody disposition in plasma and tissues in mouse models of human colorectal cancer.J Pharmacokinet Pharmacodyn. 2012 Dec;39(6):683-710. doi: 10.1007/s10928-012-9279-8. Epub 2012 Nov 27. J Pharmacokinet Pharmacodyn. 2012. PMID: 23184417 Free PMC article.
-
Physiologically-based modeling of monoclonal antibody pharmacokinetics in drug discovery and development.Drug Metab Pharmacokinet. 2019 Feb;34(1):3-13. doi: 10.1016/j.dmpk.2018.11.002. Epub 2018 Nov 22. Drug Metab Pharmacokinet. 2019. PMID: 30522890 Free PMC article. Review.
-
Development and Evaluation of Competitive Inhibitors of Trastuzumab-HER2 Binding to Bypass the Binding-Site Barrier.Front Pharmacol. 2022 Feb 18;13:837744. doi: 10.3389/fphar.2022.837744. eCollection 2022. Front Pharmacol. 2022. PMID: 35250584 Free PMC article.
-
High Affinity Promotes Internalization of Engineered Antibodies Targeting FGFR1.Int J Mol Sci. 2018 May 10;19(5):1435. doi: 10.3390/ijms19051435. Int J Mol Sci. 2018. PMID: 29748524 Free PMC article.
-
A liposomal drug platform overrides peptide ligand targeting to a cancer biomarker, irrespective of ligand affinity or density.PLoS One. 2013 Aug 23;8(8):e72938. doi: 10.1371/journal.pone.0072938. eCollection 2013. PLoS One. 2013. PMID: 24009717 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources